Department of Implantology, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, People's Republic of China.
Department of Implantology, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, People's Republic of China.
Mater Sci Eng C Mater Biol Appl. 2021 Oct;129:112376. doi: 10.1016/j.msec.2021.112376. Epub 2021 Aug 14.
Bone diseases, for example, osteoporosis, cause excessive differentiation of osteoclasts and decreased bone formation, resulting in imbalance of bone remodeling and poor osseointegration, which can be considered a relative contraindication for titanium implants. Dopamine (DA) might provide a solution to this problem by inhibiting osteoclasts and promoting osteoblasts at different concentrations. However, current commercial implants cannot load bone-active molecules, such as DA. Therefore, this study aimed to develop a surface modification method for implants to achieve a controlled release of DA and enhance the resistance of titanium implants to bone resorption and bone regeneration. DA-loaded alginate-arginine-glycine-aspartic acid (RGD) (AlgR) coatings on a vaterite-modified titanium surface were successfully assembled, which continuously and steadily released DA. In vitro studies have shown that materials showing good biocompatibility can not only inhibit receptor activator of nuclear factor-kappa B (NFκB) ligand (RANKL)-induced osteoclastogenesis but also enhance the adhesion and osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMSCs). The optimal DA-loaded concentration of this bidirectional regulation is 100 μM. Interestingly, DA more effectively attenuated osteoclastogenesis when released in a sustained manner from titanium coatings than it did via traditional, free administration, and the alginate-RGD coating and DA clearly exhibited great synergy. This study provides a design of titanium implant surface modification to improve bone remodeling around implants.
例如，骨疾病（如骨质疏松症）导致破骨细胞过度分化和骨形成减少，导致骨重建失衡和骨整合不良，这可以被认为是钛植入物的相对禁忌症。多巴胺（DA）可能通过在不同浓度下抑制破骨细胞和促进成骨细胞来解决这个问题。然而，目前的商业植入物不能加载骨活性分子，如 DA。因此，本研究旨在开发一种用于植入物的表面改性方法，以实现 DA 的控制释放，并增强钛植入物对骨吸收和骨再生的抵抗力。成功组装了载有 DA 的藻酸盐-精氨酸-甘氨酸-天冬氨酸（RGD）（AlgR）涂层在文石改性钛表面，可连续稳定地释放 DA。体外研究表明，显示良好生物相容性的材料不仅可以抑制核因子-κB 受体激活剂（NFκB）配体（RANKL）诱导的破骨细胞生成，还可以增强人骨髓间充质干细胞（hBMSCs）的黏附和成骨分化。这种双向调节的最佳 DA 载药量为 100 μM。有趣的是，与传统的自由给药相比，DA 从钛涂层中持续释放时更有效地抑制破骨细胞生成，并且藻酸盐-RGD 涂层和 DA 明显表现出很大的协同作用。本研究提供了一种钛植入物表面改性的设计，以改善植入物周围的骨重塑。
